Some FaraiFarai satire: faraifarai Sunday, 0
Post# of 72440
(Total Views: 311)
Posted On: 05/14/2017 3:34:50 PM
Re: someconcerns #33777
Some FaraiFarai satire:
faraifarai Sunday, 05/14/17 02:43:36 PM
Re: Amatuer17 post# 181929
Post # of 181951
Wow, I also can't believe how horrible the following milestones look for 2017, especially with interim analysis already in for 2 of 4. I'm thinking of writing management an angry email to say something like this, and let me know if it needs any editing:
"Dear Cellceutix Management,
I am a really disappointed shareholder. Don't get me started.
Last time I looked at the corporate presentation you uploaded on your website, I see that you have four mid-phase (phase 2 trials, for accuracy) delivering topline data this year. First of all, that's not impressive whatsoever. I mean, that's really poor. I looked hard online to find a one other biotech on the OTC with such milestones and i'll get back to you, i haven't found one yet. And I also looked on Nasdaq under the $1B market cap mark, and I also didn't find one. But I will.
But, damn it, let's get back to the real point here! I'm even more concerned because amongst these four trials, there are three lead compounds, which I'm told in biotech isn't a good thing because diversity is dangerous. Diversity, as i see it, means a lack of support if one of your drugs is to fail. It would have been SO much smarter to totally focus on one drug and keep advancing it, because statistically speaking with the FDA, the chances of success are through the roof. I'm also really, really concerned but the interim data you have posted for the Brilacidin trials, I mean, to think that in IBD your data is better than that from Nogra that completed a $2.8 billion dollar deal with Celgene. I'm also damn concerned that your Oral Mucositis trial's interim results revealed such high statistic significance in the prevention of OM that medical providers may also be disappointed because there are no effective preventatives or treatments for OM. And what the F does it say about your ABSSSI results that bettered daptomycin? I mean three trials for one stupid drug that in each trial have beat leading drugs out there and safely? To me, it means you have a loser of a drug!
Also, I really want to say what a poor job you have done advancing Prurisol as an oral for psoriasis. I know that there is only one other oral for psoriasis and it is set to earn $2B this year for Celgene and that every doctor and patient wants an oral treatment but again, there is only one approved oral in the world. Why are you guys such idiots to develop another oral that in the phase 2 trial outperformed Otezla in the 200mg arm! And Kevetrin! don't get me started on your stupid phase 2 trial for ovarian cancer. Everyone knows having a p53 drug that works, and even eventually as an oral, wouldn't be well received because there are no p53 drugs that work and that's fools mission trying to solve the holy grail of cancer treatment. Idiots!
Anyway, if you guys can get your sh*t together and run Cellceutix like a real biotech, not some rinky-dink backroom operation it's high time you did. I mean, most biotechs that i've lost money on have had only one drug in development and they've failed. the gall of you to have 3 drugs that have yet to fail a trial! Morons!
Lastly, I know nothing about your c-suite, but I think it's crazy that you can make decisions to hire and fire people however you please! I mean, at least consult me first.
Wishing you guys all the worst of luck, as I'd like nothing more than to see all of my shares accumulated at a higher price be worth nothing, as it would then prove what i've suspected all along about myself.
With extreme hatred,
Insert Name
faraifarai Sunday, 05/14/17 02:43:36 PM
Re: Amatuer17 post# 181929
Post # of 181951
Wow, I also can't believe how horrible the following milestones look for 2017, especially with interim analysis already in for 2 of 4. I'm thinking of writing management an angry email to say something like this, and let me know if it needs any editing:
"Dear Cellceutix Management,
I am a really disappointed shareholder. Don't get me started.
Last time I looked at the corporate presentation you uploaded on your website, I see that you have four mid-phase (phase 2 trials, for accuracy) delivering topline data this year. First of all, that's not impressive whatsoever. I mean, that's really poor. I looked hard online to find a one other biotech on the OTC with such milestones and i'll get back to you, i haven't found one yet. And I also looked on Nasdaq under the $1B market cap mark, and I also didn't find one. But I will.
But, damn it, let's get back to the real point here! I'm even more concerned because amongst these four trials, there are three lead compounds, which I'm told in biotech isn't a good thing because diversity is dangerous. Diversity, as i see it, means a lack of support if one of your drugs is to fail. It would have been SO much smarter to totally focus on one drug and keep advancing it, because statistically speaking with the FDA, the chances of success are through the roof. I'm also really, really concerned but the interim data you have posted for the Brilacidin trials, I mean, to think that in IBD your data is better than that from Nogra that completed a $2.8 billion dollar deal with Celgene. I'm also damn concerned that your Oral Mucositis trial's interim results revealed such high statistic significance in the prevention of OM that medical providers may also be disappointed because there are no effective preventatives or treatments for OM. And what the F does it say about your ABSSSI results that bettered daptomycin? I mean three trials for one stupid drug that in each trial have beat leading drugs out there and safely? To me, it means you have a loser of a drug!
Also, I really want to say what a poor job you have done advancing Prurisol as an oral for psoriasis. I know that there is only one other oral for psoriasis and it is set to earn $2B this year for Celgene and that every doctor and patient wants an oral treatment but again, there is only one approved oral in the world. Why are you guys such idiots to develop another oral that in the phase 2 trial outperformed Otezla in the 200mg arm! And Kevetrin! don't get me started on your stupid phase 2 trial for ovarian cancer. Everyone knows having a p53 drug that works, and even eventually as an oral, wouldn't be well received because there are no p53 drugs that work and that's fools mission trying to solve the holy grail of cancer treatment. Idiots!
Anyway, if you guys can get your sh*t together and run Cellceutix like a real biotech, not some rinky-dink backroom operation it's high time you did. I mean, most biotechs that i've lost money on have had only one drug in development and they've failed. the gall of you to have 3 drugs that have yet to fail a trial! Morons!
Lastly, I know nothing about your c-suite, but I think it's crazy that you can make decisions to hire and fire people however you please! I mean, at least consult me first.
Wishing you guys all the worst of luck, as I'd like nothing more than to see all of my shares accumulated at a higher price be worth nothing, as it would then prove what i've suspected all along about myself.
With extreme hatred,
Insert Name
(1)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼